Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Listen to expert discussions and interviews in pharma and biopharma.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
COVID-19 vaccine BNT162b2 contributes $7.8 billion in sales and alliance revenues.
July 29, 2021
By: Kristin Brooks
Pfizer 2Q Revenues: $19.0 billion (+92%) 2Q Earnings: $5.6 billion (+59%) Comments: Vaccines sales were $9.2 billion in the quarter, up from $1.2 billion in 2Q20. COVID-19 vaccine BNT162b2 contributed $7.8 billion in sales and alliance revenues. Prevnar 13 sales were up 11% to $1.3 billion. Oncology sales were $3.1 billion, up 19%. Ibrance sales were $1.4 billion, up 4%. Inlyta sales were up 32% to $257 million. Xtandi alliance revenues were $303 million, up 14%. Internal Medicine sales were $2.4 billion, up 5% driven by Eliquis sales, up 16% to $1.5 billion. Hospital sales were $2.3 billion, up 21%, primarily driven by Pfizer CentreOne, Pfizer’s contract manufacturing operation, reflecting manufacturing of legacy Upjohn products for Viatris, certain BNT162b2 manufacturing activities performed on behalf of BioNTech and remdesivir for Gilead, as well as growth from recent anti-infective product launches in international markets. Inflammation & Immunology sales were down 9% to $1.0 billion. Xeljanz sales were down 8% to $586 million and Enbrel sales were down 15% to $286 million, primarily reflecting continued biosimilar competition. Rare Disease sales were $895 million in the quarter, up 32% driven by Vyndaqel/Vyndamax, with $501 million in sales, up 81%. Biosimilars sales grew 93% to $559 million, primarily driven by recent oncology monoclonal antibody biosimilar launches of Zirabev (bevacizumab), Ruxience (rituximab) and Trazimera (trastuzumab) globally, as well as continued growth from Retacrit (epoetin) in the U.S. Following the completion of the spin-off of the Upjohn Business in 4Q20, Pfizer operates as an innovative biopharmaceutical company. Revenues and expenses associated with the Upjohn Business for the first and second quarters of 2020 have been recategorized as discontinued operations. Hospital therapeutics now includes Pfizer’s Meridian subsidiary, the manufacturer of EpiPen. Read Contract Pharma’s Top Companies Report on Pfizer.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !